HLSQ (Tessera Defense and Homeland Security Inc.) stock: $0.13, $3.4M market cap, $0.6M cash, $3.3M EV, $4.3M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
We are a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI . Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells.
Cystic fibrosis with chronic Pseudomonas aeruginosa infections(Phase 2)
Status note Dec 8, 2025: company announced discontinuation of the ongoing Phase 2b trial of BX004. BiomX Israel then commenced insolvency proceedings (Dec 2025; trustee appointed Jan 25, 2026; subsidiary deconsolidated Feb 4, 2026). Company has transitioned strategy to defense, security and critical-infrastructure technology (ZorroNet, DFSL acquisitions; X Security & Defense subsidiary) and no longer conducts pharmaceutical operations.
Per-asset detail extracted from the 10-Q filed 2026-08-19. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.